-
Something wrong with this record ?
MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy
M. Goblirsch, G. Richtig, O. Slaby, I. Berindan-Neagoe, A. Gerger, M. Pichler,
Language English Country England, Great Britain
Document type Journal Article, Review
NLK
PubMed Central
from 2015 to 1 year ago
ProQuest Central
from 2000-02-01 to 2020-12-31
Health & Medicine (ProQuest)
from 2000-02-01 to 2020-12-31
PubMed
28639472
DOI
10.2217/pgs-2017-0004
Knihovny.cz E-resources
- MeSH
- Molecular Targeted Therapy MeSH
- Colorectal Neoplasms drug therapy genetics MeSH
- Humans MeSH
- MicroRNAs genetics MeSH
- Biomarkers, Tumor genetics MeSH
- Prognosis MeSH
- Antineoplastic Agents administration & dosage therapeutic use MeSH
- Gene Expression Regulation, Neoplastic MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Colorectal cancer is a common type of malignant disease with high rates of morbidity and mortality. Although treatment options have been expanded over the last years, the mainstay of curative treatment remains surgical removal of the tumor-bearing organ. Systemic treatment options include classic cytotoxic drugs as well as some biological agents. Noncoding RNAs are an evolving field in cancer diagnosis, prognosis and possible treatment. Noncoding miRNAs are small molecules with huge impact on gene expression. They have been a substantial part of cancer research for more than a decade. In this review article, the current knowledge of miRNAs and colorectal cancer diagnosis, prognosis and novel or evolving therapeutic concepts are discussed. Examples of how miRNAs might change the management of the disease will be described.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033853
- 003
- CZ-PrNML
- 005
- 20181015114222.0
- 007
- ta
- 008
- 181008s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2217/pgs-2017-0004 $2 doi
- 035 __
- $a (PubMed)28639472
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Goblirsch, Matthew $u College of Science, Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA.
- 245 10
- $a MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy / $c M. Goblirsch, G. Richtig, O. Slaby, I. Berindan-Neagoe, A. Gerger, M. Pichler,
- 520 9_
- $a Colorectal cancer is a common type of malignant disease with high rates of morbidity and mortality. Although treatment options have been expanded over the last years, the mainstay of curative treatment remains surgical removal of the tumor-bearing organ. Systemic treatment options include classic cytotoxic drugs as well as some biological agents. Noncoding RNAs are an evolving field in cancer diagnosis, prognosis and possible treatment. Noncoding miRNAs are small molecules with huge impact on gene expression. They have been a substantial part of cancer research for more than a decade. In this review article, the current knowledge of miRNAs and colorectal cancer diagnosis, prognosis and novel or evolving therapeutic concepts are discussed. Examples of how miRNAs might change the management of the disease will be described.
- 650 _2
- $a protinádorové látky $x aplikace a dávkování $x terapeutické užití $7 D000970
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a kolorektální nádory $x farmakoterapie $x genetika $7 D015179
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mikro RNA $x genetika $7 D035683
- 650 _2
- $a cílená molekulární terapie $7 D058990
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Richtig, Georg $u Institute of Experimental & Clinical Pharmacology, Medical University of Graz, 8010 Graz, Austria.
- 700 1_
- $a Slaby, Ondrej $u Molecular Oncology II - Solid Cancers, Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Berindan-Neagoe, Ioana $u Department of Functional Genomics, The Oncology Institute, Cluj-Napoca, Romania Department of Immunology & Research Center for Functional Genomics, Biomedicine & Translational Medicine University of Medicine & Pharmacy 'I. Hatieganu' 400337 Cluj-Napoca România.
- 700 1_
- $a Gerger, Armin $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
- 700 1_
- $a Pichler, Martin $u Division of Oncology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
- 773 0_
- $w MED00008477 $t Pharmacogenomics $x 1744-8042 $g Roč. 18, č. 10 (2017), s. 1027-1038
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28639472 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181015114718 $b ABA008
- 999 __
- $a ok $b bmc $g 1340323 $s 1030847
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 18 $c 10 $d 1027-1038 $e 20170622 $i 1744-8042 $m Pharmacogenomics $n Pharmacogenomics $x MED00008477
- LZP __
- $a Pubmed-20181008
